

Tuberculosis profile: Tajikistan

Population 2019: 9.3 million

Estimates of TB burden*, 2019

	Number	(Rate per 100 000 population)
Total TB incidence	7 700 (6 000-9 700)	83 (64-104)
HIV-positive TB incidence	230 (170-300)	2.4 (1.8-3.2)
MDR/RR-TB incidence**	2 400 (1 800-3 000)	26 (20-33)
HIV-negative TB mortality	730 (650-820)	7.9 (7-8.7)
HIV-positive TB mortality	57 (40-77)	0.61 (0.43-0.83)

Estimated proportion of TB cases with MDR/RR-TB*, 2019

New cases	29% (27-31)
Previously treated cases	40% (36-45)

Universal health coverage and social protection*


TB treatment coverage (notified/estimated incidence), 2019	74% (59-97)
TB patients facing catastrophic total costs	
TB case fatality ratio (estimated mortality/estimated incidence), 2019	10% (8-13)

TB case notifications, 2019

Total new and relapse	5 755
- % tested with rapid diagnostics at time of diagnosis	85%
- % with known HIV status	98%
- % pulmonary	70%
- % bacteriologically confirmed ^	66%
- % children aged 0-14 years	7%


Incidence, New and relapse TB cases notified, HIV-positive TB incidence

(Rate per 100 000 population per year)



HIV-negative TB mortality

(Rate per 100 000 population per year)



Incidence, Notified cases by age group and sex, 2019

(Number)

- % women	40%
- % men	53%
Total cases notified	5 976

TB/HIV care in new and relapse TB patients, 2019

	Number	(%)
Patients with known HIV status who are HIV-positive	167	3%
- on antiretroviral therapy	127	76%

Drug-resistant TB care, 2019


% of bacteriologically confirmed TB cases tested for rifampicin resistance - New cases ^	100%
% of bacteriologically confirmed TB cases tested for rifampicin resistance - Previously treated cases ^	100%
Laboratory-confirmed cases - MDR/RR-TB ^^	878
Patients started on treatment - MDR/RR-TB ^^	645
Laboratory-confirmed cases - XDR-TB ^^	75
Patients started on treatment - XDR-TB ^^	68
MDR/RR-TB cases tested for resistance to any fluoroquinolone	362

Treatment success rate and cohort size


	Success	Cohort
New and relapse cases registered in 2018	89%	4 995
Previously treated cases, excluding relapse, registered in 2018	82%	155
HIV-positive TB cases registered in 2018	74%	156
MDR/RR-TB cases started on second-line treatment in 2017	64%	546
XDR-TB cases started on second-line treatment in 2017	62%	250

TB preventive treatment, 2019


% of HIV-positive people (newly enrolled in care) on preventive treatment	76%
---	-----



Treatment success rate



Total budget



% of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment 100% (100-100)

TB financing

National TB budget, 2020 (US\$ millions)	13
- Funding source, domestic	48%
- Funding source, international	44%
- unfunded	7.2%

* Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries. Ranges represent uncertainty intervals.

** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin

^ Calculated for pulmonary cases only

^^ Includes cases with unknown previous TB treatment history

^^^ Includes patients diagnosed before 2019 and patients who were not laboratory-confirmed

Generated 2020-10-21 by the World Health Organization (<https://www.who.int/tb/data/>)